Spanish healthcare acquisition in jeopardy
The Commission may challenge Grifols SA planned purchase of Talecris Biotherapeutics “on fears the merger would reduce supplies and raise prices for medicines to treat a range of autoimmune disorders,” according...To view the full article, register now.
Already a subscriber? Click here to view full article